Palladium-Catalyzed Arylation of Fluoroalkylamines
作者:Andrew T. Brusoe、John F. Hartwig
DOI:10.1021/jacs.5b02512
日期:2015.7.8
fluoroalkylaniline products are unstable under typical conditions for C-N coupling reactions (heat and strong base). However, the reactions conducted with the weaker base KOPh, which has rarely been used in cross-coupling to form C-N bonds, occurred in high yield in the presence of a catalyst derived from commercially available AdBippyPhos and [Pd(allyl)Cl]2. Under these conditions, the reactions occur with low
[EN] PALLADIUM-CATALYZED ARYLATION OF FLUOROALKYLAMINES<br/>[FR] ARYLATION CATALYSÉE PAR LE PALLADIUM DE FLUOROALKYLAMINES
申请人:UNIV CALIFORNIA
公开号:WO2016183101A1
公开(公告)日:2016-11-17
Methods for synthesizing trifluoroethyl, difluoroethyl, pentafluoropropyl, and difluorophenethyl anilines by palladium-catalyzed coupling of fluoroalkylamines with aryl bromides and aryl chlorides are provided herein. The reaction is conducted with a weaker base such as KOPh in the presence of a catalyst derived from AdBippyPhos and [Pd(allyl)Cl]2. The reactions occur with catalyst loadings less than about 0.50 mol% and tolerate the presence of various functional groups that react with the strong bases that are typically used in Pd-catalyzed C-N cross coupling reactions of aryl halides. The resting state of the catalyst is the phenoxide complex, (BippyPhosPd(Ar)OPh); due to the electron-withdrawing property of the fluoroalkyl substituent, the turn-over limiting step of the reaction is reductive elimination to form the C-N bond.
N-trifluoroethylation of anilines has been developed with 2,2,2-trifluoroethylamine hydrochloride as the fluorine source. This one-pot N–H insertion reaction is conducted via cascade diazotization/N-trifluoroethylation reactions. The developed transformation can afford a wide range of N-trifluoroethylated anilines in good yields using readily available primary amines and secondary anilines as starting materials
Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof
申请人:INVENTISBIO SHANGHAI LTD.
公开号:US10179784B2
公开(公告)日:2019-01-15
The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).